<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783482</url>
  </required_header>
  <id_info>
    <org_study_id>GC5107B_P3</org_study_id>
    <nct_id>NCT02783482</nct_id>
  </id_info>
  <brief_title>Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency</brief_title>
  <official_title>An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atlantic Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy and Pharmacokinetics of Immune
      Globulin Intravenous (Human) GC5107 in subjects with Primary Humoral Immunodeficiency (PHID).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, open-label, single-arm, historically controlled, multicenter
      phase 3 study measuring the safety, efficacy and pharmacokinetics and tolerability of GC5107
      in subjects with Primary Humoral Immunodeficiency disease (PHID).

      Subjects will receive intravenous infusions of the investigational product at the same dose
      and interval as used for their previous Immunoglobulin intravenous (IGIV) maintenance
      therapy. GC5107 will be administered every 21 or 28 days for a period of 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of acute serious bacterial infections</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of infusions with temporally associated adverse events that occur within 72 hours following an infusion of test product</measure>
    <time_frame>within 72 hours after treatment with test product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Plasma concentration-time curve of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Area under the curve (AUC0-t, AUC0-inf) of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Half life of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Volume of Distribution (Vd) of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Maximum concentration (Cmax) of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Minimum (trough) concentration (Cmin) of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Time of maximum concentration (Tmax) of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic (PK) Clearance (CL) of total Immunoglobulin G (IgG)</measure>
    <time_frame>after 5th infusion (16 weeks for 28 day schedule or 12 weeks for 21 day schedule)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough serum total IgG levels</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of infections other than acute serious bacterial infections</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days missed from work/school/kindergarten/daycare, or days unable to perform normal daily activities due to infections</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days that the care provider of the pediatric subject had to miss work in order to care for the child</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of unscheduled physician visits and hospitalizations due to infections</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of intravenous (IV) or oral therapeutic antibiotics</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of infections</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of infections other than serious bacterial infections</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall incidence of all AEs that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of test product</measure>
    <time_frame>within 72 hours after treatment with test product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of all Adverse Events (AEs) that occur during the study</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of AEs considered by the investigator to be test product related</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in safety parameters including vital signs, physical examinations and laboratory test</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of GC5107 infusions for which the infusion rate was decreased due to AEs</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of changes in viral safety (freedom from transmission of blood borne virus diseases)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetic (PK) Maximum concentration (Cmax) of specific IgG antibodies</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Immunologic Deficiency Syndromes</condition>
  <arm_group>
    <arm_group_label>GC5107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC5107 Immune globulin intravenous (human) solution, 10% liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC5107</intervention_name>
    <description>GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)</description>
    <arm_group_label>GC5107</arm_group_label>
    <other_name>IGIV</other_name>
    <other_name>Immune globulin intravenous (human) solution, 10% liquid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with a confirmed clinical diagnosis of a Primary Humoral Immunodeficiency
             Disease as defined by IUIS (International Union of Immunological Societies) and
             require treatment with IGIV. Documented agammaglobulinemia or hypogammaglobulinemia

          -  Male or Female, ages 2 to 70 years

          -  The subject has received 300-900 mg/kg of a licensed IGIV therapy at 21 or 28 day
             intervals for at least 3 months prior to this study

          -  At least 2 documented IgG trough levels of ≥ 500 mg/dL are obtained at two infusion
             cycles (21 or 28 days) within 12 months prior to study enrollment

        Exclusion Criteria:

          -  Subject has secondary immunodeficiency

          -  Subject was newly diagnosed with PHID and has not yet been treated with immunoglobulin

          -  Subject has been diagnosed with dysgammaglobulinemia or isolated IgG subclass
             deficiency or isolated IgA deficiency with known anti-IgA antibodies

          -  History of severe reaction or hypersensitivity to IGIV or other injectable form of IgG

          -  Subject has a lifetime history of at least one thrombotic event including deep vein
             thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks,
             or myocardial infarction

          -  Subject has received blood products other than human albumin or human immunoglobulin
             within 12 months prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmi Woo</last_name>
    <phone>82 31 260 9467</phone>
    <email>ahmi.woo@greencross.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Immuno International Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Issac Melamed, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Issac Melamed, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of Palm Beaches PA</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Stein, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Mark Stein, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Moy, M.D</last_name>
    </contact>
    <investigator>
      <last_name>James Moy, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Immunology Clinic and Infusion Center</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Shapiro, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Ralph Shapiro, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimed Infusions LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald McNeil, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Donald McNeil, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Institute of Allergy Ashma and Immunology</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Darter, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Amy Darter, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy Partners of North Texas Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Wasserman, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Richard Wasserman, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Specialists</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Lumry, M.D</last_name>
    </contact>
    <investigator>
      <last_name>William Lumry, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma and Immunology Clinic PA</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Suez, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Suez, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lysosomal Rare Disorder Research and Treatment Center, Inc.</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oral Alpan, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Oral Alpan, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Ritchie, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Bruce Ritchie, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Keith, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Paul Keith, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's University - Kingston General Hospital (KGH)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Ellis</last_name>
      <phone>(613) 548-2336</phone>
    </contact>
    <investigator>
      <last_name>Anne Ellis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juthaporn Cowan, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Juthaporn Cowan, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gordon Sussman Clinical Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Sussman, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Gordon Sussman, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Betschel, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Betschel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ste-Justine - University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Haddad</last_name>
      <phone>(514) 345-4713</phone>
    </contact>
    <investigator>
      <last_name>Elie Haddad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC) - The Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Mazer</last_name>
      <phone>(514) 934-1934</phone>
    </contact>
    <investigator>
      <last_name>Bruce Mazer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugo Chapdelaine, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Hugo Chapdelaine, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Spécialisée en Allergie de la Capitale</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Hébert</last_name>
      <phone>(418) 659-7741</phone>
    </contact>
    <investigator>
      <last_name>Jacques Hébert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

